Skip to main content
Top
Published in: Trials 1/2020

Open Access 01-12-2020 | Research

Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA

Authors: Ramtin Talebi, Rita F. Redberg, Joseph S. Ross

Published in: Trials | Issue 1/2020

Login to get access

Abstract

The FDA Amendments Act (FDAAA) required that information for certain clinical trials, such as details about study design features and endpoints, as well as results, be publicly reported in ClinicalTrials.​gov. We conducted a cross-sectional analysis of phase III trials with primary results published between January 1, 2016, and June 30, 2017, in high-impact journals and found 74% contained at least one discrepancy between results reported in ClinicalTrials.​gov and the corresponding publication. Our findings underscore the necessity for monitoring of clinical trial information and result reporting between sources; a checklist may provide a systemized procedure for investigators and editors to monitor accurate reporting.
Appendix
Available only for authorised users
Literature
1.
go back to reference Food and Drug Administration Amendments Act of 2007. (Public Law No. 110–85 § 801;2007.). Food and Drug Administration Amendments Act of 2007. (Public Law No. 110–85 § 801;2007.).
Metadata
Title
Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA
Authors
Ramtin Talebi
Rita F. Redberg
Joseph S. Ross
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-020-04603-9

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue